Transcatheter Mitral Valve Replacement for Severe Mitral Regurgitation: A Global Study

Transcatheter Mitral Valve Replacement for Severe Mitral RegurgitationSymptomatic mitral regurgitation is associated with high morbidity and mortality that can be alleviated partly by surgical mitral valve replacement. However, many patients do not undergo surgery. Transcatheter mitral valve replacement is an appealing option for this selected patient group.

 

This study aimed to examine the effectiveness and safety of transcatheter mitral valve replacement in a cohort of patients with native valve mitral regurgitation and high surgical risk.

 

Patients undergoing transapical transcatheter mitral valve replacement with a self-expanding prosthesis were prospectively enrolled and their short-term (30-day) outcomes were assessed.

 

Thirty high-surgical-risk patients (STS predicted risk of mortality score of 7.6 ± 5.7%) with grade 3 or 4 mitral regurgitation received the device, and there was successful implantation in 28 of them (93.3%).

 

There were no deaths, strokes, or peri-procedural infarctions. One patient died at 13 days from a hospital-acquired infection. One patient presented leaflet thrombosis that was resolved by increasing the range of anticoagulation with warfarin.

 

At 30 days, an echocardiography showed mild regurgitation in 1 patient, and absolutely none in the remaining 26 patients. There was also a significant reduction in the left ventricular end-diastolic and end-systolic volume indexes.

 

Seventy-five percent of the patients reported mild or no symptoms at follow-up.

 

Successful device implantation free of mortality, stroke, and prosthesis malfunction was 86.6%.

 

Conclusion

Transcatheter mitral valve replacement is an effective and safe therapy for selected patients with severe mitral regurgitation and high surgical risk.

 

Original title: Transcatheter Mitral Valve Replacement for Patients with Symptomatic Mitral Regurgitation. A Global Feasibility Trial.

Reference: David W.M. Muller et al. J Am Coll Cardiol. 2016 Dec 20. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...